Tag Archives: patent

The ‘Access to Medicines’ Debate: Throwing Patients Without Cures Under the Proverbial Bus

Access to Medicines

The vast majority of the world’s patients remain completely forgotten in the ‘access to medicines’ debate.   Many fail to understand how that elimination will affect the development of the cures and treatments of tomorrow, especially for rare diseases, cancers, and other serious unmet medical conditions. The Forgotten: 25 million Americans suffer from nearly 7000 rare diseases.  30 million European Union citizens suffer from between 6000 to 8000 rare diseases, 80% of which are of genetic origin Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

BIO Voices Agree: Intellectual Property Delivers

Smethurst_Aaron

Over the last year, the U.S. Chamber of Commerce’s Global IP Center (GIPC) has met with entrepreneurs from around the world to get their personal stories on what it takes to become a breakthrough innovator in the 21st century. While the products that these innovators create come in many shapes and sizes, all of those we’ve come into contact with—many of whom from the annual BIO International Convention—have displayed a resounding respect for and interest Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Pine

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2.  Patent Evergreening in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Seed Patents: How Innovation May Get Lost in the Grain Elevator

Seeds

The Bowman v. Monsanto case currently on petition for a writ of certiorari to the Supreme Court highlights some unique aspects about protecting agricultural biotechnology innovation. On April 2, the Supreme Court invited the Solicitor General to file a brief to explain the views of the United States on the Federal Circuit’s refusal to find patent exhaustion and whether an exception to that doctrine should be created for self-replicating technologies. Before making recommendations about patent Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Prior User Rights and Trade Secrets

Research

By Joe Allen, President, Allen and Associates One theme of the day is the cloud of uncertainity overhanging the US patent system. This was underscored in the Prior User Rights and Trade Secrets session at the 2012 BIO International Convention as well. The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective given by Mary Ann Dillahunty (Oncolytics Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,